XNCR · Xencor, Inc.
$24.41
+0.62% last session
End-of-day data · close of 2026-09-11
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-6.8
Dividend yield
—
Beta
0.88
Avg volume
1M
Employees
0K
Daily Change %
0.62%
5 Days Change
-6.28%
10 Days Change
-8.53%
30 Days Change
12.85%
60 Days Change
57.35%
Month to Day Change
-10.64%
Year to Day Change
62.90%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — XNCR
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-11
Latest call per bank · past 12 months
Barclays
Overweight$35.00
+44.3% vs priceJP Morgan
Neutral$21.00
-13.4% vs priceRBC Capital
Outperform$20.00
-17.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-11 | Barclays | Maintains | Overweight | $27.00 → $35.00 |
| 2026-09-03 | JP Morgan | Maintains | Neutral | $14.00 → $21.00 |
| 2026-09-01 | Raymond James | Maintains | Strong Buy | $40.00 → $46.00 |
| 2026-08-06 | RBC Capital | Maintains | Outperform | $19.00 → $20.00 |
| 2026-08-06 | Wedbush | Maintains | Outperform | $26.00 → $30.00 |
| 2026-08-06 | Cantor Fitzgerald | Maintains | Overweight | $43.00 → $44.00 |
| 2026-07-30 | Wedbush | Reiterates | Outperform | $26.00 |
| 2026-07-07 | Truist Securities | Maintains | Buy | $29.00 → $27.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 48 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 12.0% above the 50-day MA ($21.80).
- Price vs 200-day MA: Trading 59.3% above the 200-day MA ($15.32).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.72) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($8.49) and high ($29.30).
XNCR Price Chart
Loading chart for XNCR…
Fundamentals
About Xencor, Inc.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.